Skip to main content

Table 2 Safety profiles of TKI

From: Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective

Small molecule TKI CNS Nerve disorders Eye disorders Heart disorders Lung airways disorders Thyroid disorders Liver, Bile disorders
Bosutinib   XX   XX XX   XX
Dasatinib X XX XX XX XX   X
Erlotinib X XX XX   XX   X
Gefitinib    XX   XX   XX
Imatinib X XX XX X XX X XX
Lapatinib X XX   X XX   XX
Nilotinib X XX XX XX XX   XX
Pazopanib   XX XX X XX XX XX
Ponatinib   XX XX XX XX   XX
Sorafenib X XX   X X   X
Sunitinib X XX XX X XX XX X
Small molecule TKI Gastrointestinal disorders Renal disorders Musculoskeletal and bone disorders Blood and lymphatic system Vascular disorders Skin disorders CMR
Bosutinib XX XX XX XX   XX  
Dasatinib XX X X XX XX XX XX
Erlotinib XX XX   X   XX XX
Gefitinib XX XX    XX XX XX
Imatinib XX X XX XX X XX XX
Lapatinib XX   XX   XX XX XX
Nilotinib X X X XX X XX XX
Pazopanib XX XX XX XX XX XX XX
Ponatinib XX   XX XX XX XX  
Sorafenib X X X XX XX XX XX
Sunitinib XX XX XX XX XX XX XX
  1. XX = common, very common; X = rare, uncommon; CMR, carcinogenic, mutagenic and toxic for reproductive system; CNS, central nervous system; source of information: Summaries of Product Characteristics (SmPCs) of marketed TKI [16].